HBsAg-iRNA and Ara-AMP combine with thymus peptide therapy of chronic hepatitis B
-
摘要: 慢性乙型肝炎 (HBsAg+ ,HBeAg+ ,HBV -DNA+ ) 136例 ,随机分为 3组 ,第 1组 49例采用抗乙肝iRNA2mg隔日肌注 ,3个月 ,联合单磷酸阿糖腺苷 (ArA -AMP) 10mg/kg肌注 5天后 5mg/kg 2 3天 ,胸腺肽 10mg每日肌注30天。第 2组 45例用胸腺肽 90天 ,剂量和其他联合用药同 1组。第 3组 42例为对照组。治疗结束 (3个月 ) 3个组ALT复常率分别为 93 8% ,93 3% ,47 6 % ;HBeAg转阴率 32 7% ,37 8% ,9 4%HBV -DNA转阴率 34 0 % ,40 0 % ,2 4%。停药后随访一年 ,ALT复常率分别为 85 7% ,91 0 % ,5 0 0 %。HBeAg转阴率 30 6 % ,33 3% ,11 9%。HBV -DNA转阴率 30 6 % ,35 6 % ,11 9%。第 1、2两组各项与对照组比全部P <0 0 5 ,第 1与 2组各项目比P >0 0 5。提示这三种药联合治疗慢性乙型肝炎可取得部分病人持久疗效Abstract: WT5”BZ]To evaluate effects of HBsAg-iRNA and Ara-AMP combined with thymus peptide therapy of chronic hepatitis B, this was randomized trial 136 patients (HBeAg and HBV-DNA positive) were randomized into three groups, group 1 was deected with HBsAg-iRNA 2mg IM q o d 3 months, Ara-AMP 10mg/Kg, IM q d for 5 days then 5kg/Kg IM q d for 23 days and combined with thyus peptide 10 mg IM q d for 30 days Group 2 thedrugs and dosage same to group 1, but the thymus peptide IM for 90 days Group 3was control by The end of therapy (3MO) , those group 1, 2, 3 the ALT turn to recover (93 85%;93 35%;47 6%) , P<0 05, HBeAg turn to negative (32 7%;37 8%;9 4%) , HBV-DNA turn to negative (34 0%;40 0%;2 4%) , P<0 05 Follow up for one year Those group 1, 2, 3, ALT turn to recover (85 7%;91 0%;50 0%) , P<0 05 HBeAg turn to negative (30 6%;33 3%;11 9%) , P<0 05 HBV-DNA turn to negative (30 6%;35 6%;11 9%) , P<0 05 Combined with these three drags to treatment chronic hepatitis B are effective [WT5”HZ]
-
Key words:
- WT5”BZ]Chronic hepatitis B /
- HBsAg-iRNA /
- Ara-AMP /
- Thymus peptide /
-
〔1〕仉洪田 , 马本萍 , 等 Ara -AMP合用免疫调节剂治疗慢乙肝 , 中华医学杂志 , 1993 , 73∶492 〔2〕张平 , 张凌 , 仉洪田 , 等 Ara -AMP联合胸腺肽治疗慢乙肝临床观察 , 中华内科杂志 , 93 , 3 2∶119
本文二维码
计量
- 文章访问数: 2225
- HTML全文浏览量: 23
- PDF下载量: 29
- 被引次数: 0